123 related articles for article (PubMed ID: 29723451)
1. [Risks of diabetes mellitus and impaired glucose tolerance induced by intermittent versus continuous androgen-deprivation therapy for advanced prostate cancer].
Zeng S; Li ZP; Li W; Pu WZ; Liu P; Ma ZF
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):598-602. PubMed ID: 29723451
[TBL] [Abstract][Full Text] [Related]
2. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.
Tsai HT; Penson DF; Makambi KH; Lynch JH; Van Den Eeden SK; Potosky AL
Urology; 2013 Aug; 82(2):327-33. PubMed ID: 23896094
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A; Koga H; Ito K; Takezawa Y; Komiyama M; Nishimura K; Yonese J; Hashine K; Masumori N; Arai G; Saito S; Shinohara M; Shimizu N; Yamauchi A; Satoh T; Tochigi T; Kobayashi M; Fujimoto H; Kakimoto KI; Fukui I; Tsukamoto T; Nozaki M; Karasawa K; Hasumi M; Ohtani M; Ishiyama H; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Naito S; Yamanaka H;
Cancer Med; 2021 May; 10(10):3240-3248. PubMed ID: 33932114
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach.
Bonfill X; Arevalo-Rodriguez I; Martínez García L; Quintana MJ; Buitrago-Garcia D; Lobos Urbina D; Cordero JA
Cancer Manag Res; 2018; 10():2357-2367. PubMed ID: 30122985
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
9. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
10. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.
Derweesh IH; Diblasio CJ; Kincade MC; Malcolm JB; Lamar KD; Patterson AL; Kitabchi AE; Wake RW
BJU Int; 2007 Nov; 100(5):1060-5. PubMed ID: 17868420
[TBL] [Abstract][Full Text] [Related]
11. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO
Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179
[TBL] [Abstract][Full Text] [Related]
12. Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.
Parikh RA; Pascal LE; Davies BJ; Wang Z
Asian J Androl; 2014; 16(4):505-10. PubMed ID: 24759577
[TBL] [Abstract][Full Text] [Related]
13. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff JM; Abrahamsson PA; Irani J; da Silva FC
BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
[TBL] [Abstract][Full Text] [Related]
14. New Protocol of Intermittent Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer: A Retrospective Study.
Cai J; Feng G; Yan Y; Liu Z; Jing S
Clin Genitourin Cancer; 2019 Dec; 17(6):e1129-e1136. PubMed ID: 31594735
[TBL] [Abstract][Full Text] [Related]
15. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
17. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: an oral glucose tolerance test screening study.
Nowak KM; Rdzanek-Pikus M; Romanowska-Próchnicka K; Nowakowska-Płaza A; Papierska L
Rheumatology (Oxford); 2021 Jun; 60(6):2842-2851. PubMed ID: 33254223
[TBL] [Abstract][Full Text] [Related]
19. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
20. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly. The Honolulu Heart Program.
Rodriguez BL; Curb JD; Burchfiel CM; Huang B; Sharp DS; Lu GY; Fujimoto W; Yano K
Diabetes Care; 1996 Jun; 19(6):587-90. PubMed ID: 8725856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
